TY - JOUR
T1 - Effect of oral antacid administration on the pharmacokinetics of intravenous doxycyline
AU - Nguyen, V. X.
AU - Nix, D. E.
AU - Gillikin, S.
AU - Schentag, J. J.
PY - 1989
Y1 - 1989
N2 - The effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline was studied. In a randomized crossover design, six healthy male volunteers received an infusion of 200 mg of doxycycline hyclate on two occasions separated by 7 days. On one occasion, subjects were given 30 ml of aluminum hydroxide orally four times a day for 4 days, beginning 2 days prior to doxycycline dosing. Blood and urine samples were collected up to 48 and 96 h after the infusion, respectively, and were analyzed by a microbial assay. Values for volume of distribution at steady state, nonrenal clearance, urine recovery, and urine pH were not statistically different among treatment groups. With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 ± 2.6 to 11.2 ± 1.2 h (P = 0.003), and total body clearance increased from 37.4 ± 6.5 to 54.1 ± 12.3 ml/min (P = 0.008). Area under the concentration-time curve for serum was decreased by 18 to 44%, with a 22 to 41% increase in renal clearance. Although the increase in nonrenal clearance ranged from 11 to 128%, the high variability led to a nonsignificant difference (P = 0.07). Concomitant oral antacid therapy may significantly enhance the clearance of intravenous doxycycline.
AB - The effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline was studied. In a randomized crossover design, six healthy male volunteers received an infusion of 200 mg of doxycycline hyclate on two occasions separated by 7 days. On one occasion, subjects were given 30 ml of aluminum hydroxide orally four times a day for 4 days, beginning 2 days prior to doxycycline dosing. Blood and urine samples were collected up to 48 and 96 h after the infusion, respectively, and were analyzed by a microbial assay. Values for volume of distribution at steady state, nonrenal clearance, urine recovery, and urine pH were not statistically different among treatment groups. With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 ± 2.6 to 11.2 ± 1.2 h (P = 0.003), and total body clearance increased from 37.4 ± 6.5 to 54.1 ± 12.3 ml/min (P = 0.008). Area under the concentration-time curve for serum was decreased by 18 to 44%, with a 22 to 41% increase in renal clearance. Although the increase in nonrenal clearance ranged from 11 to 128%, the high variability led to a nonsignificant difference (P = 0.07). Concomitant oral antacid therapy may significantly enhance the clearance of intravenous doxycycline.
UR - http://www.scopus.com/inward/record.url?scp=0024517711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024517711&partnerID=8YFLogxK
U2 - 10.1128/AAC.33.4.434
DO - 10.1128/AAC.33.4.434
M3 - Article
C2 - 2729939
AN - SCOPUS:0024517711
SN - 0066-4804
VL - 33
SP - 434
EP - 436
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 4
ER -